Clinical Trial Update: Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing cyclophosphamide vs. infliximab for refractory idiopathic scleritis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Refractory Scleritis

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Infliximab (infliximab)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Idiopathic Refractory Scleritis | Phase 3 | Status: WITHDRAWN